Cryoprecipitate of intermediate purity produced in a closed thaw-siphon system from DDAVP stimulated blood donor plasma.
The effects of intravenous administration of DDAVP to blood donors and the use of DDAVP plasma for the production of cryoprecipitate in the closed thaw-siphon system were evaluated. DDAVP treatment produced on the average a 3.2-fold rise in plasma levels of factor VIII. Von Willebrand factor antigen increased to a lesser extent. Cryoprecipitate prepared from 220-280 ml aliquots of DDAVP stimulated donor plasma contained 472 +/- 210 units of factor VIII and 276 +/- 130 units of von Willebrand factor antigen. The average yield of factor VIII was 57% of that in the prefrozen plasma. The specific activity of factor VIII in cryoprecipitate was 0.77 +/- 0.44 U/mg protein, comparable to that for intermediate purity concentrates. Thus, by the use of DDAVP and the thaw-siphon technique it is possible to produce cryoprecipitate 4-7 times as potent as conventionally manufactured preparations.
Konecka
G
G
Department of Blood Storage and Preparation, Institute of Haematology, Warsaw, Poland.
Bykowska
K
K
Ludwicka
A
A
Letowska
M
M
Wegrzynowicz
Z
Z
Sablinski
J
J
Lopaciuk
S
S
D001782:Blood Donors; D011232:Chemical Precipitation; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage* / Q000494:pharmacology; D005169:Factor VIII / Q000187:drug effects / Q000302:isolation & purification / Q000378:metabolism*; D005615:Freezing; D006801:Humans; D008297:Male; D012016:Reference Values; D014841:von Willebrand Factor / Q000302:isolation & purification
D014841:von Willebrand Factor; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin